{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:47:21Z","timestamp":1772916441116,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bladder cancer (BC) is the ninth most prevalent malignancy worldwide. It remains a significant clinical burden due to high recurrence rates and the need for reliable, non-invasive diagnostic tools. Metabolomics is a powerful strategy for non-invasive cancer detection, with urine representing an ideal biofluid for biomarker discovery, given its direct contact with the urinary tract and its rich diversity of metabolites. This study aimed to identify urinary metabolites showing significant differences in urinary levels between BC patients and controls, and to evaluate their potential for diagnosis and disease monitoring. Beyond identifying metabolites differentiating BC patients from controls, we also assessed whether urinary metabolic patterns could distinguish BC subtypes [non\u2013muscle invasive BC (NMIBC) versus muscle-invasive BC (MIBC)]. Following chemical derivatization, urinary samples were analysed by gas chromatography\u2013mass spectrometry, and the resulting datasets were evaluated using univariate and multivariate statistical approaches. Among the 32 metabolites identified (e.g. amino acids, organic acids, alcohols, and sugar-derivatives), lactate was identified as significantly upregulated in BC versus controls, particularly in MIBC cases. Receiver operating characteristic analysis demonstrated a good performance for overall BC detection and in discriminating between MIBC and NMIBC cases. These results, independent of smoking status and sex, position lactate as a promising non-invasive biomarker for invasive BC.<\/jats:p>","DOI":"10.1093\/molecular-omics\/aaiag004","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:22:36Z","timestamp":1770643356000},"source":"Crossref","is-referenced-by-count":0,"title":["Urinary metabolomics identifies lactate as a biomarker for bladder cancer detection and progression"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-4485","authenticated-orcid":false,"given":"\u00c2ngela","family":"Carapito","sequence":"first","affiliation":[{"name":"Associate Laboratory i4HB \u2013 Institute for Health and Bioeconomy, University of Porto , 4050-313 Porto ,","place":["Portugal"]},{"name":"UCIBIO \u2013 Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto , 4050-313 Porto ,","place":["Portugal"]}]},{"given":"Tiago","family":"Vieira de Sousa","sequence":"additional","affiliation":[{"name":"Associate Laboratory i4HB \u2013 Institute for Health and Bioeconomy, University of Porto , 4050-313 Porto ,","place":["Portugal"]},{"name":"UCIBIO \u2013 Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto , 4050-313 Porto ,","place":["Portugal"]}]},{"given":"Ana","family":"Teixeira-Marques","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) \/ Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) , 4200-072 Porto ,","place":["Portugal"]},{"name":"Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto , 4050-313 Porto ,","place":["Portugal"]}]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) \/ Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) , 4200-072 Porto ,","place":["Portugal"]},{"name":"Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto , 4050-313 Porto ,","place":["Portugal"]},{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto) \/ Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) , 4200-072 Porto ,","place":["Portugal"]}]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) \/ Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC) , 4200-072 Porto ,","place":["Portugal"]},{"name":"Department of Pathology and Molecular Immunology, ICBAS-School of Medicine and Biomedical Sciences, University of Porto , 4050-313 Porto ,","place":["Portugal"]}]},{"given":"Ana Cec\u00edlia A","family":"Roque","sequence":"additional","affiliation":[{"name":"Associate Laboratory i4HB \u2013 Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University of Lisbon , 2829-516 Caparica ,","place":["Portugal"]},{"name":"UCIBIO \u2013 Applied Molecular Biosciences Unit, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon , 2829-516 Caparica ,","place":["Portugal"]}]},{"given":"F\u00e9lix","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Associate Laboratory i4HB \u2013 Institute for Health and Bioeconomy, University of Porto , 4050-313 Porto ,","place":["Portugal"]},{"name":"UCIBIO \u2013 Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto , 4050-313 Porto ,","place":["Portugal"]}]},{"given":"Joana","family":"Pinto","sequence":"additional","affiliation":[{"name":"Associate Laboratory i4HB \u2013 Institute for Health and Bioeconomy, University of Porto , 4050-313 Porto ,","place":["Portugal"]},{"name":"UCIBIO \u2013 Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto , 4050-313 Porto ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-5700","authenticated-orcid":false,"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[{"name":"Associate Laboratory i4HB \u2013 Institute for Health and Bioeconomy, University of Porto , 4050-313 Porto ,","place":["Portugal"]},{"name":"UCIBIO \u2013 Applied Molecular Biosciences Unit, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto , 4050-313 Porto ,","place":["Portugal"]}]}],"member":"286","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2026030622115919700_ref1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"2026030622115919700_ref2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026030622115919700_ref3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.urolonc.2020.08.016","article-title":"Urinary biomarkers in bladder cancer: a review of the current landscape and future directions","volume":"39","author":"Ng","year":"2021","journal-title":"Urol Oncol"},{"key":"2026030622115919700_ref4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00005392-200102000-00081","article-title":"Urine based markers of urological malignancy","volume":"165","author":"Konety","year":"2001","journal-title":"J Urol"},{"key":"2026030622115919700_ref5","doi-asserted-by":"crossref","first-page":"e73076","DOI":"10.1371\/journal.pone.0073076","article-title":"The human urine metabolome","volume":"8","author":"Bouatra","year":"2013","journal-title":"PLoS One"},{"key":"2026030622115919700_ref6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/0929867324666170914102236","article-title":"Current trends in cancer biomarker discovery using urinary metabolomics: achievements and new challenges","volume":"26","author":"Burton","year":"2018","journal-title":"Curr Med Chem"},{"key":"2026030622115919700_ref7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ajur.2022.11.005","article-title":"Metabolomics for the diagnosis of bladder cancer: a systematic review","volume":"11","author":"Garc\u00eda-Perdomo","year":"2023","journal-title":"Asian J Urol"},{"key":"2026030622115919700_ref8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fonc.2020.00102","article-title":"Traditional classification and novel subtyping systems for bladder cancer","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"2026030622115919700_ref9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-030-51652-9_2","article-title":"NMR-based metabolomics","volume":"1280","author":"Nagana Gowda","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"2026030622115919700_ref10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12953-025-00241-8","article-title":"Mass-spectrometry based metabolomics: an overview of workflows, strategies, data analysis and applications","volume":"23","author":"Hajnajafi","year":"2025","journal-title":"Proteome Sci"},{"key":"2026030622115919700_ref11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/imm.13871","article-title":"Metabolic reprogramming in cancer: implications for immunosuppressive microenvironment","volume":"174","author":"Aden","year":"2025","journal-title":"Immunology"},{"key":"2026030622115919700_ref12","doi-asserted-by":"crossref","first-page":"763902","DOI":"10.3389\/fmolb.2021.763902","article-title":"Recent metabolomics analysis in tumor metabolism reprogramming","volume":"8","author":"Han","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026030622115919700_ref13","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/nprot.2011.375","article-title":"Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry","volume":"6","author":"Chan","year":"2011","journal-title":"Nat Protoc"},{"key":"2026030622115919700_ref14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/metabo8010023","article-title":"GC-MS-based endometabolome analysis differentiates prostate cancer from normal prostate cells","volume":"8","author":"Lima","year":"2018","journal-title":"Metabolites"},{"key":"2026030622115919700_ref15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11306-020-01691-1","article-title":"New findings on urinary prostate cancer metabolome through combined GC\u2013MS and 1H NMR analytical platforms","volume":"16","author":"Lima","year":"2020","journal-title":"Metabolomics"},{"key":"2026030622115919700_ref16","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.pex-2143\/v1","article-title":"Tutorial on PARADISe: PARAFAC2-based deconvolution and identification system for processing GC-MS data","volume-title":"PROTOCOL (Version 1) available at Protocol Exchange","author":"Quintanilla-Casas"},{"key":"2026030622115919700_ref17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cbpa.2017.01.001","article-title":"How close are we to complete annotation of metabolomes?","volume":"36","author":"Viant","year":"2017","journal-title":"Curr Opin Chem Biol"},{"key":"2026030622115919700_ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkae253","article-title":"MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation","volume":"52","author":"Pang","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026030622115919700_ref19","article-title":"R: A language and environment for statistical computing","volume-title":"R Foundation for Statistical Computing. Vienna, Austria, 2021","author":"R Core Team","year":"2024"},{"key":"2026030622115919700_ref20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate. A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Statist Soc B"},{"key":"2026030622115919700_ref21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.patrec.2005.10.010","article-title":"An introduction to ROC analysis","volume":"27","author":"Fawcett","year":"2006","journal-title":"Pattern Recogn Lett"},{"key":"2026030622115919700_ref22","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1111\/cas.15047","article-title":"The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets","volume":"112","author":"Burns","year":"2021","journal-title":"Cancer Sci"},{"key":"2026030622115919700_ref23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/cc1518","article-title":"Bench-to-bedside review: lactate and the kidney","volume":"6","author":"Bellomo","year":"2002","journal-title":"Crit Care"},{"key":"2026030622115919700_ref24","doi-asserted-by":"crossref","first-page":"e115870","DOI":"10.1371\/journal.pone.0115870","article-title":"Bladder cancer biomarker discovery using global metabolomic profiling of urine","volume":"9","author":"Wittmann","year":"2014","journal-title":"PLoS One"},{"key":"2026030622115919700_ref25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2174\/0929867324666171006150326","article-title":"Metabolomic heterogeneity of urogenital tract cancers analyzed by complementary chromatographic techniques coupled with mass spectrometry","volume":"26","author":"Yumba-Mpanga","year":"2019","journal-title":"Curr Med Chem"},{"key":"2026030622115919700_ref26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.talanta.2019.05.039","article-title":"Urinary metabolomic signature of muscle-invasive bladder cancer: a multiplatform approach","volume":"202","author":"Jacyna","year":"2019","journal-title":"Talanta"},{"key":"2026030622115919700_ref27","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1021\/pr4000448","article-title":"Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry","volume":"12","author":"Pasikanti","year":"2013","journal-title":"J Proteome Res"},{"key":"2026030622115919700_ref28","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1021\/pr4004135","article-title":"HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease","volume":"12","author":"Tripathi","year":"2013","journal-title":"J Proteome Res"},{"key":"2026030622115919700_ref29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3390\/cancers11050686","article-title":"Integrative metabolomic and transcriptomic analysis for the study of bladder cancer","volume":"11","author":"Loras","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026030622115919700_ref30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2116\/analsci.28.451","article-title":"NMR-based metabolomic analysis of human bladder cancer","volume":"28","author":"Cao","year":"2012","journal-title":"Anal Sci"},{"key":"2026030622115919700_ref31","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1021\/pr400859w","article-title":"Low- and high-grade bladder cancer determination via human serum-based metabolomics approach","volume":"12","author":"Bansal","year":"2013","journal-title":"J Proteome Res"}],"container-title":["Molecular Omics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/molecular-omics\/advance-article-pdf\/doi\/10.1093\/molecular-omics\/aaiag004\/66818971\/aaiag004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/molecular-omics\/article-pdf\/22\/2\/aaiag004\/66818971\/aaiag004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/molecular-omics\/article-pdf\/22\/2\/aaiag004\/66818971\/aaiag004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:12:11Z","timestamp":1772853131000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/molecular-omics\/article\/doi\/10.1093\/molecular-omics\/aaiag004\/8469216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1093\/molecular-omics\/aaiag004","relation":{},"ISSN":["2515-4184"],"issn-type":[{"value":"2515-4184","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,9]]},"article-number":"aaiag004"}}